[1] Johnson P, Zhou Q, Dao D Y, et al. Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(10): 670-681. [2] Okabe H, Delgado E, Lee J M, et al. Role of leukocyte cell-derived chemotaxin 2 as a biomarker in hepatocellular carcinoma[J]. PLoS One, 2014, 9(6): e98817. [3] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 肿瘤综合治疗电子杂志, 2020, 6(02): 55-85. [4] Galle P R, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int, 2019, 39(12): 2214-2229. [5] Hanif H, Ali M J, Susheela A T, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma[J]. World J Gastroenterol, 2022, 28(2): 216-229. [6] Hu X, Chen R, Wei Q, et al. The landscape of Alpha fetoprotein in hepatocellular carcinoma: where are we?[J]. Int J Biol Sci, 2022, 18(2): 536-551. [7] Yu Z, Chen D, Zheng Y, et al. Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2023, 149(13): 11295-11308. [8] Benson A B, D′Angelica M I, Abbott D E, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5): 541-565. [9] Yao C, Wu S, Kong J, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies[J]. Cancer Biol Med, 2023, 20(1): 25-43. [10] Yang Z, Cai J, Wang Y, et al. Comparison of doppler imaging and microvascular imaging in cervical lymph node blood flow analysis[J]. Curr Med Imaging, 2024, 20(1): e1591100949. [11] Muppala S. Growth factor-induced angiogenesis in hepatocellular carcinoma[J]. Crit Rev Oncog, 2021, 26(1): 61-68. [12] Ainora M E, Cerrito L, Liguori A, et al. Multiparametric dynamic ultrasound approach for differential diagnosis of primary liver tumors[J]. Int J Mol Sci, 2023, 24(10). [13] Xie Y, Fan K W, Guan S X, et al. LECT2: A pleiotropic and promising hepatokine, from bench to bedside[J]. J Cell Mol Med, 2022, 26(13): 3598-3607. [14] Chu T H, Ko C Y, Tai P H, et al. Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma[J]. J Biol Chem, 2022, 298(10): 102442. [15] Chen C K, Yu W H, Cheng T Y, et al. Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis[J]. Sci Rep, 2016, 631398. |